not enough, page-2

This board is pathetic. Peter Cook has been a disappointment and is milking the company dried. What hope has the shareholders got if they are around.

Question:

1. Jane Ryan BSc (Hons), Vice President, Product Development
Dr Jane Ryan joined Biota in 1997. What value has she added in the last 11 years?


2. Leigh Farrell BSc (Hons), FAICD, Vice President, Business Development, Dr Leigh Farrell was appointed Vice President, Business Development on 24 April 2006.

What did this guy do for the last two years?

3. Simon Tucker BSc (Hons), PhD, Vice President, Research
Dr Simon Tucker joined Biota in 1997.

What research outcome did we see in the last 11 years?

4. John Lambert BSc (Hons), MRACI, C.Chem.
Principal Director, Product Development Operations, Dr John Lambert joined Biota in 2002 as Head of Chemistry and became Director of Reseach for the U.S. operation, Biota Inc., in 2004. On returning from the U.S., Dr Lambert became Executive Director, Drug Discovery and in 2007 became Principal Director, Product Development Operations.

Now this guy calls himself Principal Director product development operations. What products did he developed in the last 6 years?


It seems that these fancy titles people only good at having their hands in the honeypot. Are they worth the value to shareholders?




quote from Biota's site:

John Grant CA, MBA
Chairman, Non-Executive Director

John Grant joined the Board on the 30th August 2001. He brings over twenty years of successful experience in private equity investing in Australia and overseas. He was the joint founder of Hambro-Grantham Limited, a Venture Capital firm. Under his leadership, Hambro-Grantham invested in over 70 primarily technology based businesses through the provision of start-ups, expansion and buyout finance. In 2004 he chaired the Commonwealth of Australia Investment Review of Health and Medical Research. John is also Chairman of Bioplatforms Australia Limited. He is a Director of Research Australia Limited and John Swire & Sons Pty Limited. He was a former Chairman of the New Zealand Venture Investment Fund Limited and AMBRI Limited and Director of Colonial First State Private Capital Limited.


Barbara Gibson BSc, FTSE, MAICD
Non-Executive Director

Barbara Gibson was appointed a Director in April 1996. Barbara possesses a broad array of business management experience, particularly in the commercialisation of technologies. She was formerly the General Manager Chemicals Group of Orica Limited, a member of the Orica Group Executive and a Director of Incitec Pivot Limited. Prior to this role she was the General Manager of Advanced Sciences Group, which included the Pharmaceuticals, Diagnostics and other Healthcare businesses of Orica. Barbara is Chairman of Warakirri Asset Management Pty Ltd and is a Director of Penrice Soda Holdings Limited and St Barbara Limited. She is also a member of the Australian Academy of Technological Sciences and Engineering.


Ian Gust AO. MD, MBS, BSc, DipBact(Lond), FRCPA, FRACP, MASM, FTS
Non-Executive Director

Age 64 Ian Gust was appointed a Director on the 27th July 2001. He has had a long and distinguished career in medical research and has received wide international recognition for his contributions to the field of virology. Ian was the former Director of Research and Development at CSL Limited, a position he held for ten years (1990-2000). During this period he was closely involved in CSL's successful expansion in Australia and internationally. He is currently a Professorial Fellow, Department of Microbiology and Immunology, University of Melbourne; a consultant to the Bill and Melinda Gates' Children's Vaccine Program; and a consultant to UNICEF and the World Health Organisation (WHO). Ian is a member of the Remuneration Committee.


Grant Latta AM B.Bus, MBA, CPA, FAICD, FAIM, AAMI, Cert. Eng
Non-Executive Director

Grant Latta joined the Board on the 9th February 2006. He is an experienced company director and senior business executive with strong financial management, marketing and strategic skills which he has gained through a depth of successful domestic and international business experience in large and emerging companies. Grant is Executive Chairman of GCMCorp Pty Ltd, Chairman of Optiscan Imaging Limited and Kailis & France Foods Pty Ltd. He is a Director of Ricegrowers Limited and Coleambally Irrigation Co-operative Limited and a member of the Australian Competition Tribunal to the Federal Court. He was formerly Chairman of the Grains Research and Development Corporation and TP Health Limited, Deputy Chairman of Food Science Australia, Deputy Chairman of Export Finance and Insurance Corporation and Director of Austrade.

Grant is Chair of the Audit & Risk Committee.


Paul Bell BA, MA (Hons)
Non-Executive Director

Paul Bell was appointed a Director on 8 September 2006.

Mr Bell has had an extensive executive career with the international pharmaceutical company Merck & Co Inc. He is a former member of Merck's Management Committee and was President of their Asia Pacific Human Health Division between 1997 and 2002.

Paul is currently a Director of Cochlear Limited and Bio-Link Partners Ltd. Mr Bell is also Chairman of Westmead Millennium Institute Advisory Board, a Member of the Pharmaceutical Partnerships Program Committee and a Member of the Business Development Advisory Board of Garvan Institute of Medical Research.

Paul is Chairman of the Remuneration & Nominations Committee.


Peter Cook M.Pharm., FRMIT, PhC., MPS, MRACI, C.Chem., MAICD.
Chief Executive Officer and Managing Director

Peter Cook was appointed Chief Executive Officer and Managing Director on the 9th December 2005.

Prior to joining Biota, he was Chief Executive Officer and Managing Director of Orbital Corporation Limited, a powertrain engineering company with unique technologies in direct injection of internal combustion engines. Mr Cook previously held the positions of Chief Executive Officer of Faulding Pharmaceuticals, President of Ansell's Protective Products Division, Deputy Managing Director of Invetech and Director of Research and Development for Nicholas Kiwi. He has had extensive experience in restructures, mergers and acquisitions, innovation and innovation commercialisation with technology-based companies and has a strong manufacturing background. Mr Cook has extensive business experience within Australia, and has over ten years of international commercial experience in Europe, USA and Asia, where he has both lived and worked. Mr Cook holds a Masters Degree in Pharmacy and post graduate qualifications in Management. He is a non executive Director of Quickstep Holdings Limited.


Damian Lismore BA (Hons), FCA, MAICD
Chief Financial Officer and Company Secretary

Damian was appointed Chief Financial Officer on 26 August 2005.

His commercial background includes ten years with Price Waterhouse (now PwC) in Australia and six years with Deloittes Haskins & Sells in the UK. More recently, he has served as Group Financial Controller and General Manager Buying & Finance for the major Australian pharmaceutical company, Sigma; and as Managing Director of MNT Innovations, the commercial arm of the CRC (Co-operative Research Centre) for MicroTechnology.

Damian has extensive experience at all levels of the healthcare industry, particularly in acquisitions and restructures, commercialisation of new technologies and dealing with the investment community.

He holds a Bachelor of Arts (Honours) in Accountancy, is a Fellow of the Institute of Chartered Accountants and a member of the Australian Institute of Company Directors.


Jane Ryan BSc (Hons)
Vice President, Product Development

Dr Jane Ryan joined Biota in 1997.

Dr Ryan has many years of international experience in the pharmaceutical/ biotechnology industry including 10 years experience gained overseas.

Dr Ryan has worked at Roche and Columbia University in the USA and with Peptech and Cambridge Antibody Technology in the UK. Since returning to Australia, she has worked with Peptech before joining Biota Holdings Ltd where she has had roles in managing commercialisation of internal and external programs as well as business development, licensing and alliance management. She is now the Vice President, Product Development.

Jane has been a member of the Board of Diabetes Australia Victoria since 1997. Recently she became a member of the Board of Bio Innovation SA.


Leigh Farrell BSc (Hons), FAICD
Vice President, Business Development

Dr Leigh Farrell was appointed Vice President, Business Development on 24 April 2006.

Prior to joining Biota, Dr Farrell spent approximately 4 years as an Associate Director at GBS Ventures Partners Limited, a specialist Life Sciences Venture Capital Fund. Dr Farrell previously held the positions of Research Manager at Johnson & Johnson Research Pty Ltd and Chief Executive Officer of Gene Shears Pty Limited.

Dr Farrell has extensive international experience in corporate finance, business development, licensing, relationship management and intellectual property portfolio management in the biotechnology and pharmaceutical industries.


Simon Tucker BSc (Hons), PhD
Vice President, Research

Dr Simon Tucker joined Biota in 1997.

Dr Tucker has over 20 years of scientific and commercial experience in research and development. Prior to joining Biota in 1997 he held leadership positions in the U.S. pharmaceutical company, GD Searle and Universities of Alabama (USA) and Glasgow (UK). Dr Tucker has extensive international experience in biotechnology and pharmaceutical research and development, intellectual property management, research and development alliance management, licensing and related areas.


John Lambert BSc (Hons), MRACI, C.Chem.
Principal Director, Product Development Operations

Dr John Lambert joined Biota in 2002 as Head of Chemistry and became Director of Reseach for the U.S. operation, Biota Inc., in 2004. On returning from the U.S., Dr Lambert became Executive Director, Drug Discovery and in 2007 became Principal Director, Product Development Operations.

Prior to joining Biota, John was Senior Lecturer at the University of Melbourne and is a co-founder of the biotechnology startup company Cryptopharma Pty Ltd.

Dr Lambert graduated with a PhD from the University of Melbourne and undertook post-doctoral studies at Harvard University, USA and the Australian National University, where he held a Queen Elizabeth II Fellowship. He has been the recipient of many other distinguished awards for his contributions to chemistry including the Royal Australian Chemical Institute's inaugural Cornforth Medal.